Novel P397S MAPT variant associated with late onset and slow progressive frontotemporal dementia

Sergi Borrego-Écija1, Anna Antonell1, Joan Anton Puig-Butillé2

  • 1Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clinic, Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.

Insights

A new mutation in the MAPT gene, p.P397S, is linked to frontotemporal dementia. This genetic variant may cause a milder form of the disease compared to other MAPT mutations.

Area of Science:

  • Neuroscience
  • Genetics
  • Neurology

Background:

  • Mutations in the MAPT gene are a known cause of frontotemporal dementia (FTD).
  • FTD is characterized by progressive neurodegeneration and tau protein deposits.

Observation:

  • A novel MAPT variant, p.P397S, was identified in eight individuals across five families with frontotemporal dementia.
  • The inheritance pattern observed was autosomal dominant.
  • In silico analyses provided conflicting results regarding the variant's pathogenicity.

Findings:

  • Segregation analysis indicated that the p.P397S variant is likely pathogenic.
  • Individuals with the p.P397S variant had a later age of onset (mean 61.4 years) and longer disease duration (mean 13.9 years) compared to carriers of the p.P301L MAPT mutation.
  • These findings suggest p.P397S is associated with a less aggressive FTD phenotype.

Implications:

  • The p.P397S variant represents a new genetic cause of frontotemporal dementia.
  • This discovery expands the spectrum of MAPT mutations associated with FTD.
  • The identification of a less aggressive phenotype associated with p.P397S could inform future diagnostic and therapeutic strategies for FTD.

Related Concept Videos

Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
533
Histone Variants at the Centromere02:30

Histone Variants at the Centromere

Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3...
5.0K
Gene Evolution - Fast or Slow?02:05

Gene Evolution - Fast or Slow?

The genomes of eukaryotes are punctuated by long stretches of sequence which do not code for proteins or RNAs. Although some of these regions do contain crucial regulatory sequences, the vast majority of this DNA serves no known function. Typically, these regions of the genome are the ones in which the fastest change, in evolutionary terms, is observed, because there is typically little to no selection pressure acting on these regions to preserve their sequences.
In contrast, regions which code...
8.0K
Gene Evolution - Fast or Slow?02:05

Gene Evolution - Fast or Slow?

3.4K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K